Unanswered questions

Author: | Published: 29 May 2018

There are very few people who are willing to discuss the pending mega merger between American publically traded agro biotech company Monsanto, and the German megalithic life science and pharma company Bayer. The deal is worth a reported $66 billion and has unsurprisingly piqued the interest of antitrust agencies across the world.

After some research, I saw some (many) fairly crucial issues with the deal. For one thing, the statistics suggest that Monsanto already owns far more than what should be considered as acceptable level in several key industries like cotton, soy or corn. Why is it acceptable for...